macular dystrophy


Also found in: Dictionary, Thesaurus, Encyclopedia.
Related to macular dystrophy: macular corneal dystrophy

mac·u·lar ret·i·nal dys·tro·phy

(mak'yū-lahr ret'i-năl dis'trŏ-fē)
A group of disorders predominantly involving the posterior portion of the ocular fundus, due to degeneration in the sensory layer of the retina, retinal pigment epithelium, Bruch membrane, choroid, or a combination of these tissues.
See: Stargardt disease, Best disease
Synonym(s): macular dystrophy.

macular dystrophy

Any inherited, progressive degeneration of the macula lutea retinae marked by progressive central visual loss beginning in childhood or adolescence. Representative forms of macular dystrophy include Best disease and Stargardt disease. See: macula lutea retinae
See also: dystrophy
References in periodicals archive ?
Another recent report publishes the findings of a clinical trial in which ESC-derived RPE cells (MA09-hRPE) were applied to the subretinal space in a total of four cases, two with dry AMD and two with Stargardt macular dystrophy. No adverse side effects were observed in one year of follow-up.
Stargardt's disease or Stargardt's macular dystrophy is a genetic disease that causes progressive vision loss, usually starting in children between 10 to 20 years of age.
Medicine company Advanced Cell Technology Inc (OTCBB:ACTC) reported on Monday the initiation of the treatment of the first patient with better vision in the patient cohort 2a of its US clinical trial for Stargardt's Macular Dystrophy (SMD), a form of juvenile macular degeneration.
"We are looking forward to collaborating with ACT to evaluate the potential of the stem cell-derived RPE [retinal pigment epithelial] cells for debilitating diseases such as Stargardt's macular dystrophy and dry AMD." For more information, contact: Wills Eye Institute, 840 Walnut Street, Philadelphia, PA 19107; phone: 215-928-3000; web site: <www.willseye.org>.
They suffer from Stargardt's macular dystrophy, a disease which develops in childhood and affects around one in 10,000 people.
Advanced Cell Technology (ACT), Worster, MA, announced the first patients in its two Phase 1-2 clinical trials for Stargardt's Macular Dystrophy (SMD) and Dry Aged-Related Macular Degeneration (Dry AMD) using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs).
22 became the second company to win permission from the FDA to conduct a trial of human embryonic stem cells, in that case to treat Stargardt macular dystrophy, a rare form of macular degeneration that strikes children.
The latest treatment involves injecting the retinal cells derived from human embryonic stem cells, into the eyes of patients with Stargardt's Macular Dystrophy, a disease which affects around 25,000 people in the United States.
The 47-year-old mumof-three, who has a hereditary disease called macular dystrophy, felt her chances of a "normal" life were over.
The search wasn't easy, but then again, not much in life has been for Whitsell - a 27-year-old who was diagnosed with macular dystrophy when she was 9.

Full browser ?